Download Image
    
Share
  
Post
FX06 for COVID-19
1 study with 49 patients
Hospital Icon Control
Hospital Icon FX06 Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 FX06 studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -10% Mortality -10% RCTs -10% Late -10% FavorsFX06 Favorscontrol
Aug 29
2023
 Guérin et al., Critical Care, doi:10.1186/s13054-023-04616-1 FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial
10% higher mortality (p=1). RCT 49 patients with COVID-19-associated ARDS showing no significant effect of FX06 on vascular leakage or mortality.